Covid-19 clinical trial integrity

Health Action International and TranspariMED's May 2022 report on Covid-19 clinical trial integrity – impact on global health and the future European regulatory agenda demonstrates how chaotic and uncoordinated research surrounding potential Covid-19 treatments have been. In the early months of the pandemic, hundreds of trials were quickly conducted, often by non-commercial sponsors with no prior experience. With this trend continuing throughout the pandemic, the report found rampant duplication of research efforts, weak trial designs, and research waste. This has had a clear negative impact on global health, with several patients dying because of delays in identifying effective treatments.